Startseite Kongressberichte 2019 ESMO 2019 SAKK Studien am ESMO 2019

SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial

Presenter: Antonia Digklia

Conclusions

These preliminary results indicate that biweekly administration of nab-PC/gem was well tolerated. The phase I established dose and schedule were selected for further evaluation in phase II trial.

 

Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)

Presenter: Michael Mark

Conclusions

The majority of the pts was treated according to current guideline recommendations with regard to start and interval of BTA treatment. The number of SREs was low irrespective of BTA treatment or risk classification for SREs, which may reflect a high impact of systemic cancer treatment on SRE reduction, or a selection of the pts according to risk factors not defined as the ones in the literature. 

 

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Presenter: Salah-Eddin Al-Batran

Planned Trial

This study evaluates atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with FLOT.
 

SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm Phase II trial.

Presenter: Yannis Metaxas

Conclusions

The primary efficacy endpoint was reached with acceptable toxicity. Lurbinectedin showed promising activity compared to historical data. Neither histology nor prior IO seems to affect efficacy of lurbinectedin, but respective pts numbers are small for definitive conclusions. Further evaluation of lurbinectedin in a large randomized trial is warranted.